Market Intelligence, Clinical Progress, and High-Purity Reagents for ADPKD Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Polycystin 1/PKD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PKD1 ECD-Fc Fusion Protein (Rational Truncation) & Mutant Proteins High purity (>95%), HEK293 Expressed (Native Glycosylation), Endotoxin <1 EU/ug. Sequence Verified. |
View PKD1 Products |
| Gene Delivery | PKD1 Lentivirus Premade Particles (Full-length ORF, 11.2 kb) CMV/EF1a promoter options for stable cell lines preserving native membrane topology. |
View PKD1 Products |
| Complex Partner | PKD2/TRPP2 Protein & Lentivirus For heterodimer complex validation; sequence-verified co-expression available. |
View PKD2 Products |
| Validator | PKD1 siRNA Set (3 Unique Sequences) Knockdown verification and specificity controls for ADPKD models; includes scrambled control. |
View PKD1 Products |
| Benchmark Ab | Anti-PKD1 (Sequence of Reference Biosimilar) Recombinant positive control for assay standardization. |
View PKD1 Products |
| Related Target A | PKHD1 (Fibrocystin) ARPKD-associated polycystin; structural homology for comparative studies. |
View PKHD1 Products |
| Related Target B | TRPV4 Ion Channel Mechanosensory pathway component; functional coupling with polycystin complex. |
View TRPV4 Products |
| Related Target C | AVPR2 (Vasopressin V2 Receptor) Downstream pathway modulator; standard-of-care target for ADPKD combination studies. |
View AVPR2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length PKD1 Expression (430 kDa, 11-TM) | Lentivirus-mediated stable cell lines preserving native topology and ciliary trafficking capability |
| PKD1/PKD2 Complex Formation | Co-expression systems; Human/Mouse/Cyno ortholog proteins available for cross-species validation |
| Mechanosensitive Channel Function | Cell-based assays using lentivirus-transduced MDCK or HK-2 cells with calcium flux readouts |
| Specificity Controls | Sequence-verified siRNA and scrambled controls included; Theoretical MW confirmed by SDS-PAGE |
| Endotoxin Sensitivity in Kidney Models | Endotoxin <1 EU/ug verified by LAL assay; Low endotoxin batch certification available |
| Extracellular Domain Truncation Stability | Sequence Verified, High Purity (>95%) rationally designed ECD-Fc fusions produced in HEK293 with native glycosylation |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
Live PKD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Autosomal Dominant Polycystic Kidney Disease (ADPKD) is transitioning from symptomatic management (vasopressin V2 receptor antagonists like Tolvaptan) to disease-modifying approaches directly targeting the PKD1/PKD2 polycystin complex. Tolvaptan remains the sole approved therapy, acting indirectly via V2 receptor blockade to slow cyst growth. The next wave of R&D is shifting toward genetic modulation strategies: RNA interference (targeting miR-17 which regulates PKD1 expression) is being explored by Regulus Therapeutics (RG-012, now discontinued with Sanofi but validated concept); small molecule chaperones that stabilize mutant PKD1 folding and promote ciliary trafficking represent another dominant modality. Additionally, gene therapy/mRNA approaches (e.g., CRISPR repair or full-length ORF delivery) are intensifying despite AAV vector capacity limitations (PKD1 gene ~11.2 kb). As first-generation genetic therapies enter Phase II, critical assays must evolve to measure polycystin complex restoration rather than simple ligand binding, requiring full-length protein expression systems, ciliary localization validation, and functional channel assays.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi (Anti-miR-17) | Regulus Therapeutics, Sanofi (past) | ADPKD (Early Stage) | qPCR validation of PKD1 mRNA rescue; Requires high-specificity siRNA controls |
| Small Mol Chaperones | Otsuka, Academic Consortia | ADPKD (ER Retention Mutants) | Cell-based trafficking assay using Lentivirus-PKD1 stable lines with cilia markers |
| Gene Therapy / mRNA | Regulus, Early-stage Biotechs | ADPKD | Expression Validation (Need specific Abs & Lentivirus controls) |
| Gene Editing (CRISPR) | Crispr Therapeutics, Editas | Genetic Correction | Homology-directed repair validation; Full-length PKD1 lentivirus for rescue experiments |
| Bispecific (PKD1/PKD2 Stabilizers) | Emerging Academic Programs | Complex Stabilization | Heterodimer SPR/BLI assays using purified ECD-Fc fusions |
| Small Molecule Channel Modulators | Sanofi, Otsuka | ADPKD, CKD | Functional Channel Assays (Need stable PKD1/PKD2 co-expressing cell lines via Lentivirus) |
Conclusion: Why TarMart for PKD1 Research?
PKD1 is a challenging membrane protein target (430 kDa, 11-transmembrane domains) requiring native conformation for functional studies. TarMart's Lentivirus-based cell models enable full-length PKD1 expression with proper ciliary trafficking, while high-purity ECD-Fc proteins (>95%, low endotoxin) support biochemical binding assays. Our multi-species ortholog panel (Human/Mouse/Cyno) facilitates cross-species validation for preclinical translation, and bundled PKD1/PKD2 complex reagents accelerate ADPKD drug discovery from target validation to lead optimization.